Exam (elaborations)
PHAR 100 Midterm review exam questions and answers
PHAR 100 Midterm review exam questions and answers
[Show more]
Preview 2 out of 11 pages
Uploaded on
November 15, 2024
Number of pages
11
Written in
2024/2025
Type
Exam (elaborations)
Contains
Questions & answers
Institution
PHAR 100
Course
PHAR 100
$12.99
100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached
PHAR 100 Midterm review exam
questions and answers
Drugs ii- iiAnswers ii-Any iisubstance iireceived iiby iia iiliving iiorganism iiwithout iinutritional
iivalue iiand iiinfluences iibiological iifunctions
Pharmacology ii- iiAnswers ii-The iistudy iiof iiuse, iieffects iiand iimode iiof iiaction iiof iidrugs
Ancient iiGreece, iiChina iiand iiEgypt ii- iiAnswers ii-These iiancient iicivilizations iiplayed iia
iimajor iirole iiin iidrug iidevelopment
Ergotamine ii- iiAnswers ii-Drug iicomponent iiuse iito iitreat iimigraines
Ergonovine ii- iiAnswers ii-Drug iithat iiused iito iibe iiused iito iihasten iiuterus iicontraction.
iiNow iiused iito iistop iiuterine iibleeding iiafter iichildbirth
chlorpromazine ii- iiAnswers ii-Tranquilizing iiagent iithat iiacts iion iithe iibrain, iibeneficial iifor
iimentally iiill iipatients
reserpine ii- iiAnswers ii-Tranquilizing iiagent, iiacting iion iithe iibrain, iiwith iithe iisame
iimechanism iiof iiaction iias iichlorpromazine iibut iinot iioften iiused iibecause iiit iiis iidifficult
iito iidetermine iithe iiright iidose
Lysergic iiAcid iiDiethylamide ii(LSD) ii- iiAnswers ii-Drug iiacting iion iithe iibrain iiwith iimajor
iipsychedelic iieffects iithat iihas iisimilar iimechanisms iiof iiaction iito iiergotamine iiand
iiergonovine
Nitrous iioxide iiand iiether ii- iiAnswers ii-Drugs iiacting iion iithe iibrain; iithese iiwere iithe iifirst
iitwo iitypes iiof iianesthetics iidiscovered iiinitially iiused iifor iidental iiextractions
Drug iiDevelopment iiProcess ii- iiAnswers ii-includes iiresearch iiand iidiscovery iiof iitarget
ii(receptor), iipharmacological iieffects iiat iithe iimolecular, iicellular iiand iiorgan iilevels
Toxicology iistudies ii- iiAnswers ii-Studies iiused iito iidetermine iithe iieffects iiof iithe iidrug
iion iithe iirest iiof iithe iisystem iibesides iithe iitarget iisite iiof iiaction
Pharmacology iistudies ii- iiAnswers ii-Determine iithe iidetailed iimechanism iiof iithe iidrug
Steps iiof iia iiclinical iitrial ii- iiAnswers ii-Initial iisteps, iiPhase iiI, iiPhase iiII, iiPhase iiIII
, Initial iisteps iiof iia iiclinical iitrial ii- iiAnswers ii-Submit iiproof iiof iisafety iiand iiefficacy iion
iianimals, iisubmit iimethodology, iipermission iigiven iito iistart iitesting iiwith iiextraordinary
iiprecaution.
Phase iiI iiclinical iitrial ii- iiAnswers ii-Clinical iitrial iiphase iiwith iilimited iinumber iiof
iivolunteers iiwhere iionly iithe iisafety iiis iitested. iiAbsorption, iidistribution iiand iielimination
iiis iicarefully iievaluated. iiOne iior iitwo iidoses iito iidetermine iitolerance, iiefficacy iiis iinot
iitested iiat iithis iistage
Phase iiII iiclinical iitrial ii- iiAnswers ii-Clinical iitrial iiphase iiwith iipatients iiwith iithe iidisease
iithe iidrug iiis iidesigned iito iitreat iito iidetermine iiwhether iithe iidrug iiis iieffective iiand
iimonitor iisafety iiand iiside iieffects.
Phase iiIII iiclinical iitrial ii- iiAnswers ii-Clinical iitrial iiphase iitested iion iia iilarge iinumber iiof
iipeople iito iidetermine iisafety iiand iiefficacy.
Elements iiof iia iiphase ii3 iiclinical iitrial ii- iiAnswers ii-Informed iiconsent,
iiinclusion/exclusion iicriteria, iirandomized iiallocation, iidouble-blind iiprocedure, iipatient
iicompliance
Drug iimanufacturing ii- iiAnswers ii-Use iiof iia iigeneric iivs iia iibrand iiname iibecause
iiscientific iinames iiare iitoo iicomplicated iifor iipatients. iiDrug iipatents
Phase ii4 iiclinical iitrial ii- iiAnswers ii-Post-marketing iisurveillance iifor iiany iiside iieffects
iimissed iiduring iithe iiclinical iitrial.
Receptors ii- iiAnswers ii-primary iidrug iitargets iilocated iiin iithe iibody iiwith iiindividual
iiregulatory iifunctions iiactivated iiby iihormones iiand iineurotransmitters
Agonists ii- iiAnswers ii-Drug iithat iibinds iito iistimulate iithe iireceptor
Antagonist ii- iiAnswers ii-Drug iithat iibinds iito iiblock iithe iiresponse iiof iithe iireceptors
Drug iitargets ii- iiAnswers ii-Receptors
Dose iiresponse iirelationship ii- iiAnswers ii-the iirelationship iibetween iithe iidifferent iidoses
iiand iithe iiresponses iithey iigenerate
Dose iiresponse iicurve ii- iiAnswers ii-Log iidose iiresponse iimaking iianalysis iieasier. iiThe
iicurve iirepresents iithe iithreshold iiof iieffect iiand iithe iimaximum iieffect iiis iiobtained iiat
iithat iiplateaux.
Efficacy ii- iiAnswers ii-Maximum iipharmacological iiresponse iithat iican iibe iiproduced iiby
iia iidrug iiin iia iiparticular iisystem ii(regardless iiof iithe iidose)
Potency ii- iiAnswers ii-Dose iirequired iito iireach ii50% iiof iithe iidesired iiresponse